{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T21:31:00Z","timestamp":1776893460681,"version":"3.51.2"},"reference-count":57,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.7674","type":"journal-article","created":{"date-parts":[[2017,4,30]],"date-time":"2017-04-30T22:11:21Z","timestamp":1493590281000},"page":"993-999","source":"Crossref","is-referenced-by-count":18,"title":["Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome"],"prefix":"10.2169","volume":"56","author":[{"given":"Ryo","family":"Katsumata","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal medicine, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Shiotani","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal medicine, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Murao","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal medicine, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal medicine, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Fujita","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal medicine, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal medicine, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Haruma","sequence":"additional","affiliation":[{"name":"Department of General Internal medicine 2, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10: 712-721, 2012.","DOI":"10.1016\/j.cgh.2012.02.029"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Adeyemo MA, Spiegel BM, Chang L. Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? Aliment Pharmacol Ther 32: 738-755, 2010.","DOI":"10.1111\/j.1365-2036.2010.04409.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shiotani A, Miyanishi T, Takahashi T. Sex differences in irritable bowel syndrome in Japanese university students. J Gastroenterol 4: 562-568, 2006.","DOI":"10.1007\/s00535-006-1805-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 13: 1149-1159, 1999.","DOI":"10.1046\/j.1365-2036.1999.00610.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Vo\u00df U, Lewerenz A, Nieber K. Treatment of irritable bowel syndrome: sex and gender specific aspects. Handb Exp Pharmacol 214: 473-497, 2012.","DOI":"10.1007\/978-3-642-30726-3_21"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fukudo S, Kinoshita Y, Okumura T, et al. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. J Gastroenterol 150: 358-366.e8, 2016.","DOI":"10.1053\/j.gastro.2015.10.047"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 43: 1202-1211, 2008.","DOI":"10.1080\/00365520802240255"},{"key":"8","unstructured":"8. Miwa H. Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria. Patient Prefer Adherence 2: 143-147, 2008."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cremon C, Carini G, Wang B, et al. Intestinal release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 106: 1290-1298, 2011.","DOI":"10.1038\/ajg.2011.86"},{"key":"10","unstructured":"10. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 95: 2698-2709, 2000."},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of by a second tryptophan hydroxylase isoform. Science 299: 76, 2003.","DOI":"10.1126\/science.1078197"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 16: 2352-2364, 1996.","DOI":"10.1523\/JNEUROSCI.16-07-02352.1996"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal content and decreased reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126: 1657-1664, 2004.","DOI":"10.1053\/j.gastro.2004.03.013"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kerckhoffs AP, ter Linde JJ, Akkermans LM, Samsom M. SERT and TPH-1 mRNA expression are reduced in irritable bowel syndrome patients regardless of visceral sensitivity state in large intestine. Am J Physiol Gastrointest Liver Physiol 302: G1053-G1060, 2012.","DOI":"10.1152\/ajpgi.00153.2011"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Daub B, Schroeter M, Pfitzer G, Ganitkevich V. Expression of members of the <i>S100<\/i> Ca2+-binding protein family in guinea-pig smooth muscle. Cell Calcium 33: 1-10, 2003.","DOI":"10.1016\/S0143-4160(02)00167-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Donato R. Intracellular and extracellular roles of <i>S100<\/i> proteins. Microsc Res Tech 60: 540-551, 2003.","DOI":"10.1002\/jemt.10296"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Foell D, Roth J. Proinflammatory <i>S100<\/i> proteins in arthritis and autoimmune disease. Arthritis Rheum 50: 3762-3771, 2004.","DOI":"10.1002\/art.20631"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Roth J, Vogl T, Sorg C, Sunderkotter C. Phagocyte-specific <i>S100<\/i> proteins: a novel group of proinflammatory molecules. Trends Immunol 24: 155-158, 2003.","DOI":"10.1016\/S1471-4906(03)00062-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Leach ST, Yang Z, Messina I, et al. Serum and mucosal <i>S100<\/i> proteins, calprotectin (<i>S100A8<\/i>\/<i>S100A9<\/i>) and <i>S100A12<\/i>, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 42: 1321-1331, 2007.","DOI":"10.1080\/00365520701416709"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 58: 859-868, 2007.","DOI":"10.1136\/gut.2008.170019"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the <i>s100<\/i> protein family in inflammatory bowel disease. Dig Dis Sci 56: 1601-1611, 2011.","DOI":"10.1007\/s10620-010-1494-9"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Rana SV, Sharma S, Sinha SK, Parsad KK, Malik A, Singh K. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop Gastroenterol 33: 251-256, 2012.","DOI":"10.7869\/tg.2012.66"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn&apos;s disease. Gut 47: 506-513, 2000.","DOI":"10.1136\/gut.47.4.506"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 49: 861-867, 2003.","DOI":"10.1373\/49.6.861"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119: 15-22, 2000.","DOI":"10.1053\/gast.2000.8523"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Shiotani A, Kusunoki H, Kimura Y, et al. <i>S100A<\/i> expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome. Dig Dis Sci 58: 2314-2323, 2013.","DOI":"10.1007\/s10620-013-2677-y"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Donier E, Rugiero F, Okuse K, Wood JN. Annexin II light chain p11 promotes functional expression of acid-sensing ion channel ASIC1a. J Biol Chem 280: 38666-38672, 2005.","DOI":"10.1074\/jbc.M505981200"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Cervero F, Laird JM. Understanding the signaling and transmission of visceral nociceptive events. J Neurobiol 61: 45-54, 2004.","DOI":"10.1002\/neu.20084"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Svenningsson P, Chergui K, Rachleff I, et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311: 77-80, 2006.","DOI":"10.1126\/science.1117571"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Alexander B, Warner-Schmidt J, Eriksson T, et al. Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med 2: 54ra76, 2010.","DOI":"10.1126\/scitranslmed.3001079"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Camilleri M, Andrews CN, Bharucha AE, et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 132: 17-25, 2007.","DOI":"10.1053\/j.gastro.2006.11.020"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130: 1480-1491, 2006.","DOI":"10.1053\/j.gastro.2005.11.061"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Essien BE, Grasberger H, Romain RD, et al. ZBP-89 regulates expression of tryptophan hydroxylase I and mucosal defense against <i>Salmonella<\/i> typhimurium in mice. Gastroenterology 144: 1466-1477, 2013.","DOI":"10.1053\/j.gastro.2013.01.057"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33: 129-134, 1988.","DOI":"10.1007\/BF01535722"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Zung W. A self-rating depression scale. Arch Gen Psychiatry 12: 63-70, 1965.","DOI":"10.1001\/archpsyc.1965.01720310065008"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122: 1778-1783, 2002.","DOI":"10.1053\/gast.2002.33579"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Shulman RJ, Jarrett ME, Cain KC, Broussard EK, Heitkemper MM. Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. J Gastroenterol 49: 1467-1476, 2014.","DOI":"10.1007\/s00535-013-0919-6"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 136: 1979-1988, 2009.","DOI":"10.1053\/j.gastro.2009.02.074"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Thabane M, Simunovic M, Akhtar-Danesh N, Marshall JK. Development and validation of a risk score for post-infectious irritable bowel syndrome. Am J Gastroenterol 104: 2267-2274, 2009.","DOI":"10.1038\/ajg.2009.302"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 110: 444-454, 2015.","DOI":"10.1038\/ajg.2015.6"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Kirsch R, Riddell RH. Histopathological alterations in irritable bowel syndrome. Mod Pathol 19: 1638-1645, 2006.","DOI":"10.1038\/modpathol.3800704"},{"key":"42","unstructured":"42. Chen JJ, Li Z, Pan H, et al. Maintenance of in the intestinal mucosa and ganglia of mice that lack the high-affinity transporter: Abnormal intestinal motility and the expression of cation transporters. J Neurosci 21: 6348-6361, 2001."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Spigset O. Adverse reactions of selective reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 20: 277-287, 1999.","DOI":"10.2165\/00002018-199920030-00007"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44. Gorard DA, Libby GW, Farthing MJ. 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut 35: 496-500, 1994.","DOI":"10.1136\/gut.35.4.496"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med 6: 152-167, 2009.","DOI":"10.1016\/j.genm.2009.03.004"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Herman J, Pokkunuri V, Braham L, Pimentel M. Gender distribution in irritable bowel syndrome is proportional to the severity of constipation relative to diarrhea. Gend Med 7: 240-246, 2010.","DOI":"10.1016\/j.genm.2010.06.007"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Franke L, Schmidtmann M, Riedl A, van der Voort I, Uebelhack R, M\u00f6nnikes H. Serotonin transporter activity and concentration in platelets of patients with irritable bowel syndrome: effect of gender. J Gastroenterol 45: 389-398, 2010.","DOI":"10.1007\/s00535-009-0167-y"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Warner-Schmidt JL, Flajolet M, Maller A, et al. Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci 29: 1937-1946, 2009.","DOI":"10.1523\/JNEUROSCI.5343-08.2009"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554, 2002.","DOI":"10.1016\/S0091-3057(01)00746-8"},{"key":"50","doi-asserted-by":"publisher","unstructured":"50. Hoffman JM, Tyler K, MacEachern SJ, et al. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 142: 844-854, 2012.","DOI":"10.1053\/j.gastro.2011.12.041"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Shiotani A, Kusunoki H, Ishii M, Imamura H, et al. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of <i>S100A10<\/i> and polymorphisms of TPH1. Neurogastroenterol Motil 27: 82-91, 2015.","DOI":"10.1111\/nmo.12473"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Heitkemper M, Jarrett M, Bond EF, Chang L. Impact of sex and gender on irritable bowel syndrome. Biol Res Nurs 5: 56-65, 2003.","DOI":"10.1177\/1099800403005001006"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Di Nardo G, Barbara G, Cucchiara S, et al. Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS. Neurogastroenterol Motil 26: 196-204, 2014.","DOI":"10.1111\/nmo.12250"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Gonzalez-Castro AM, Martinez C, Salvo-Romero E, et al. Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in Irritable Bowel Syndrome. J Gastroenterol Hepatol 2016 (Epub ahead of print).","DOI":"10.1111\/jgh.13417"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Meleine M, Matricon J. Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones. World J Gastroenterol 20: 6725-6743, 2014.","DOI":"10.3748\/wjg.v20.i22.6725"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Thakur ER, Gurtman MB, Keefer L, Brenner DM, Lackner JM. Gender differences in irritable bowel syndrome: the interpersonal connection. Neurogastroenterol Motil 27: 1478-1486, 2015.","DOI":"10.1111\/nmo.12647"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Bale TL, Epperson CN. Sex differences and stress across the lifespan. Nat Neurosci 18: 1413-1420, 2015.","DOI":"10.1038\/nn.4112"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/9\/56_56.7674\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T15:38:57Z","timestamp":1569166737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/9\/56_56.7674\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.7674","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}